Announcements

Job Offers

Top 5 -yesterday

Top 5 -last week

Top 5 -last month

AU: THC Global commences production deal with Cannatrek

THC Global Group and Cannatrek Limited have agreed to a cannabis supply and manufacturing agreement. "This agreement takes advantage of THC Global’s Southport Facility as a high volume world-class pharmaceutical production facility, and Cannatrek’s significant cannabis cultivation expertise," the team with the company explains. "Cannatrek is a leading grower of medicinal cannabis in Australia, with growing facilities located outside Brisbane, growing a number of cannabis strains with diverse cannabinoid levels. Cannatrek are also developing a new facility in Shepparton, Victoria which was granted Major Project Status by the Australian Government as a new greenfield development."

"Through THC Global’s ownership of the extraction process, on-site laboratories for product development and validation, and a pathway to patient access through Tetra Health, THC Global can offer a complete solution for expert cannabis cultivators like Cannatrek."

"Further, alongside THC Global’s low cost of medicines production at its Southport Facility, this arrangement is a low cost means of acquiring cannabis plant material to scale up proprietary medicines production. This arrangement with Cannatrek is greatly beneficial for the Australian medicinal cannabis industry and for Australian patients by delivering more choices of high quality Australian produced medicines."

THC Global CEO, Ken Charteris, commented: “This is a significant milestone for THC Global and Cannatrek, but also for the Australian medicinal cannabis industry. By utilising our Southport Facility to produce high quality medicinal cannabis medicines for Cannatrek’s brand as well as our Canndeo brand, we’re increasing the number of Australian produced medicines available to patients, and supporting the development of the industry as a whole.

“I look forward to seeing production with Cannatrek commence shortly, and invite other cultivators to explore partnering with THC Global.” Cannatrek CEO, Tommy Huppert, commented: “The Australian medicinal cannabis industry is maturing rapidly in 2020 and the THC Global-Cannatrek production agreement provides excellent opportunities for deploying both agronomic and manufacturing excellence in the supply chain but more importantly, will allow patients to have access to 100% Australian made medicinal cannabis for therapeutic purposes, at a more affordable price.” First supply of dried cannabis flower from Cannatrek under this arrangement is expected to commence in Q3 2020, with first Cannatrek branded medicines to be released by THC Global in Q4 2020 following production and validation.

For more information:
THC Global Group
Level 2,
131 Macquarie St
Sydney NSW 2000 
+61 (0)2 9251 7177 
thc.global    


Publication date:



Receive the daily newsletter in your email for free | Click here


Other news in this sector:


Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber